161. Coppola S.

Berni Canani R

Di Scala C.

Luzzetti A.

Nocerino R.

Paparo L.

Voto L.

English

Archivio della ricerca - Università degli studi di Napoli Federico II

XLI CONGRESSO NAZIONALE SINU - 9-10 / 16-17 APRILE 2021Stato: INVIATO - ID: 7527BUTYRATE AGAINST PAEDIATRIC OBESITY: RESULTS OF THE BAPO TRIALS. Coppola1,2, R. Nocerino1,2, L. Paparo1,2, C. Di Scala1,2, L. Voto1,2, A. Luzzetti1,2, V. Giglio1,2, R. Berni Canani1,2,3,41Dipartimento di Scienze Mediche Traslazionali, Università degli Studi di Napoli Federico II2ImmunoNutrition Lab, CEINGE Biotecnologie Avanzate, Università degli Studi di Napoli Federico II3Laboratorio Europeo per lo studio delle malattie indotte da alimenti (ELFID), Università degli Studi di Napoli Federico II4Task Force di Ateneo per gli Studi sul Microbioma, Università degli Studi di Napoli Federico IIObjectives and StudyPaediatric obesity is global public health challenges. Preclinical studies have shown that the short chain fatty acid butyrate could exertbeneficial effects against obesity. We aimed to see whether oral butyrate could exert beneficial effects in obese children/adolescents.MethodsThe BAPO trial (butyrate against paediatric obesity) was a randomized, quadruple-blind, placebo controlled, clinical trial on obesepaediatric patients (Body Mass Index (BMI) >95th percentile for age and sex) of both sexes, aged 7-16 years, observed at a tertiary centerfor paediatric nutrition. After collection of informed consent by the patients and their tutors/parents, subjects were randomly assignedaccording to the randomization list to one of the two 6-month intervention groups: active group, standard care for paediatric obesity +sodium butyrate (20 mg/kg body weight/day); or placebo group, standard care for paediatric obesity + placebo. Study products wereprovided in capsules packed in identical boxes with the same aspect, color and weight. The primary outcome was a BMI z-score reductionof  ≥ 0.25 after 6-month intervention. Secondary outcomes were the evaluation of BMI, waist circumference, HOMA-index and eatingbehaviors (using a 3-day food record). At baseline and at the end of treatment, a blood sample was collected from all study subjectsto evaluate fasting glucose, fasting insulin, plasma triglycerides, total/LDL/and HDL cholesterol, fasting serum ghrelin and miRNA-221expression (a miRNA obesity related, whose expression was assessed in peripheral mononuclear blood cells PBMCs).Results54 obese patients were enrolled and randomly assigned to two intervention groups (27 per group); 6 subjects were lost to follow up and48 subjects completed the study: 23 in active group and 25 in placebo group. At baseline, main demographic and clinical features of the2 study groups were similar. The rate of subjects with BMI z-score reduction of ≥ 0.25 was significantly lower in active groups comparedto placebo group. At the end of intervention, a significant reduction of daily calories intake and a macronutrient redistribution toward therecommended range were observed in both groups. Waist circumference and BMI was significant lower in active group at the end ofintervention. A significant reduction of fasting insulin, HOMA-index and LDL was observed in active group. Finally, a significant down-regulation of peripheral miR-221 expression and a significant decrease of fasting serum ghrelin was observed in patients treated withsodium butyrate.ConclusionsThis is the first evidence of the therapeutic role of butyrate in paediatric obesity. Our preliminary results suggest that the beneficial effectsare mediated in part by epigenetic mechanism, involving miRNA 221 expression, and by hormonal regulation of food intake played byghrelin, a relevant regulator of appetite, body weight and energy homeostasis.

Butyrate against paediatric obesity: results of the BAPO trial

https://www.iris.unina.it/bitstream/11588/850898/1/Abstract%20SINU%20Coppola.pdf

Butyrate against paediatric obesity: results of the BAPO trial

Abstract

Similar works

Full text

Available Versions

Archivio della ricerca - Università degli studi di Napoli Federico II